Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
National Cancer Institute (NCI)
BioNTech SE
Bristol-Myers Squibb
Canadian Cancer Trials Group
AbbVie
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Henlius Biotech
Bristol-Myers Squibb
NRG Oncology
Cancer Research UK
AbbVie
Hoffmann-La Roche
Second Affiliated Hospital of Nanchang University
TJ Biopharma Co., Ltd.
Eikon Therapeutics
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Pfizer
Rigshospitalet, Denmark
Shanghai Henlius Biotech
SWOG Cancer Research Network
Cancer Research UK
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Alpha Biopharma (Jiangsu) Co., Ltd.
Medicine Invention Design, Inc
Swiss Cancer Institute
Hansoh BioMedical R&D Company
Medicine Invention Design, Inc
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Medicine Invention Design, Inc
PhytoHealth Corporation
SWOG Cancer Research Network
Canadian Cancer Trials Group
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University
Hunan Province Tumor Hospital
Guy's and St Thomas' NHS Foundation Trust
Shanghai Shengdi Pharmaceutical Co., Ltd
Shanghai JMT-Bio Inc.
Amphera BV
Institute of Cancer Research, United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China
Laibin People's Hospital
Canadian Cancer Trials Group
Fudan University
University of California, San Francisco
Chang Gung Memorial Hospital
Jiangsu Alphamab Biopharmaceuticals Co., Ltd